The Foundation for Prader-Willi Research

The Foundation for Prader-Willi Research (federal tax id 31-1763110) is a nonprofit corporation with federal tax-exempt status as a public charity under section 501(c)(3).

Susan Hedstrom

Executive Director

Dr. Theresa Strong

Director of Research Programs

6 past transactions

Aardvark Therapeutics

Series C in 2024
Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing and commercializing small molecule therapeutics for obesity and rare genetic metabolic disorders. Founded in 2017 by Tien Lee, the company has introduced Bittera, a first-in-class oral composition designed to selectively disrupt hunger signaling and regulate energy homeostasis. This innovative therapeutic approach provides clinicians with an effective and safe treatment option for obesity-related diseases, without interfering with nutrient absorption. Aardvark Therapeutics aims to address significant health challenges associated with obesity and metabolic conditions through its specialized drug development efforts.

Palobiofarma

Convertible Note in 2023
Palobiofarma is a Spanish biotechnology company based in Barcelona's Science Park, dedicated to the discovery and development of new drugs that target adenosine receptors. The company aims to be a leader in adenosine drug discovery in Europe by focusing on innovative therapies. Palobiofarma specializes in creating selective adenosine receptor modulators, with a particular emphasis on addressing advanced prostate cancer. By leveraging medicinal chemistry and in vitro pharmacology, the company is working towards bringing its first marketed drug to the medical community, supporting healthcare professionals in their efforts to treat this challenging disease.

Aardvark Therapeutics

Series B in 2021
Aardvark Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing and commercializing small molecule therapeutics for obesity and rare genetic metabolic disorders. Founded in 2017 by Tien Lee, the company has introduced Bittera, a first-in-class oral composition designed to selectively disrupt hunger signaling and regulate energy homeostasis. This innovative therapeutic approach provides clinicians with an effective and safe treatment option for obesity-related diseases, without interfering with nutrient absorption. Aardvark Therapeutics aims to address significant health challenges associated with obesity and metabolic conditions through its specialized drug development efforts.

Beryl Therapeutics

Venture Round in 2021
Beryl Therapeutics goal is to open up a new frontier in bone health based on the revelation that lipids are crucial signaling molecules that play a role in bone mass regulation. Beryl is developing a patented first-in-class small molecule to increase peak bone mass and cure poor bone mineral density caused by disease or natural aging.

Lipidio Pharmaceuticals

Series A in 2020
Lipidio Pharmaceuticals Inc. is a biopharmaceutical company based in San Diego, California, focused on developing treatments for diseases associated with excess body fat. Founded in 2018, the company's lead drug candidate, GDD3898, targets conditions such as Prader-Willi syndrome, nonalcoholic steatohepatitis (NASH), and weight gain related to antipsychotic medications. Lipidio Pharmaceuticals aims to address significant unmet medical needs in both metabolic disorders and dermatological conditions, including sebaceous hyperplasia and moderate to severe acne. The company's innovative approach seeks to enhance treatment options for healthcare professionals managing these challenging health issues.

Inversago Pharma

Series A in 2018
Inversago Pharma Inc. is a preclinical-stage biotechnology company based in Montreal, Canada, focused on developing innovative therapies targeting metabolic and fibrotic disorders. The company specializes in peripherally-restricted CB1 receptor inverse agonists, which aim to offer new treatment options for conditions such as Prader-Willi syndrome, diabetes, and related metabolic disorders. Inversago Pharma's research includes addressing complications associated with diabetic kidney disease, non-alcoholic steatohepatitis, and various fibrotic diseases, including interstitial lung disease. Founded in 2015, the company is dedicated to enhancing patient outcomes through its pioneering approach to CB1 blockade.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.